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Introduction
B-lymphoid tyrosine kinase (BLK) is a member of the 
canonical group of SRC family kinases (SFKs). In humans, 
this group contains the eight closely related non-receptor 
tyrosine kinases: SRC, YES1, FYN, FGR, LCK, LYN, 
HCK, and BLK, all characterized by the presence of a SH3 
and a SH2 domain N-terminal to the catalytic kinase domain. 
The SFKs are found to be associated with transmembrane 
receptors and activated by extracellular receptor stimula-
tion. In turn, SFKs transmit receptor signals and regulate a 
wide range of cellular processes, including proliferation, 
survival, migration, differentiation, and angiogenesis.1 
Several members of the SFKs are known to function as 
oncogenes in a variety of malignancies. For instance, SRC 
is an oncogene involved in several malignancies including 
colon, breast, lung, and pancreatic cancer.2 Likewise, other 
SFKs such as FYN, YES1, and LYN have also been impli-
cated in several solid malignancies.3–5 SFKs are also impli-
cated in hematological cancers. For instance, both HCK and 
LYN are important players in malignant BCR-ABL signal-
ing pathways of chronic myelogeneous leukemia (CML), 
and LCK has been implicated in B-cell chronic lymphocytic 
leukemia (B-CLL) and T-cell acute lymphoblastic leukemia 
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(T-ALL).6–10 The importance of SFKs in many malignancies 
is widely acknowledged and has spurred the development of 
SFK inhibitors, including the dual-specific SFK and BCR-
ABL-inhibitor dasatinib, which has proven to be a valuable 
drug in cancer therapy.11,12 Most of the SFKs exhibit tissue-
specific expression patterns with several members being 
expressed primarily in distinct subsets of the lymphoid line-
age where they are recognized for their involvement in lym-
phocyte antigen receptor–mediated signaling.13–15 BLK is 
normally expressed in B-cells and is involved in B-cell anti-
gen receptor signaling.16–23 Several lines of evidence sug-
gest that BLK may also have oncogenic properties. 
Transgenic mice expressing a constitutively active murine 
Blk in their lymphoid compartment developed lymphoma-
tous B- and T-cell-like disorders providing evidence of a 
transforming potential of this murine orthologue.24 Recently, 
we reported that a constitutively active form of human BLK 
was able to transform the lymphocytic Ba/F3 cells into 
growth factor independency by conferring resistance to 
apoptosis induced by cytokine withdrawal in vitro.25 The 
first indications of a potential oncogenic role of BLK in 
human cancer were the discoveries of an ectopic expression 
of BLK in malignant T-cells in lesional skin biopsies from 
patients with cutaneous T-cell lymphoma (CTCL) and the 
findings that BLK was constitutively active in malignant 
T-cells and promoted proliferation of CTCL cell lines in 
vitro.26 In addition, dasatinib inhibited growth of CTCL cell 
xenografts in mice.25 Taken together, these findings suggest 
that BLK might have an oncogenic function in CTCL.25,26 
Interestingly, a recent study has demonstrated ectopic 
expression of BLK in treatment-resistant patients with adult 
T-cell leukemia lymphoma (ATLL), suggesting functional 
importance of BLK in drug resistance in T-cell malignancies.27 
Notably, ectopic expression of BLK in other hematological 
cancers along with a multitude of non-hematological can-
cers and cancer cell lines suggests that BLK—like other 
SFKs—may have an important role in malignant transfor-
mation and cancer development.28,29 One study has shown 
that BLK may delay BCR-ABL-driven malignant develop-
ment in CML and thus suggests a contextual role of BLK in 
tumor development.30 Taken together, these findings indi-
cate that ectopic expression and constitutive activation of 
BLK is a potential oncogenic signal pathway in T-cell 
malignancies and possibly other human cancers. Here, we 
report that constitutively active human BLK is an oncogene 
with the capacity to induce tumors in mice. Furthermore, we 
demonstrate a novel mouse model for future mechanistic 
and therapeutic studies of BLK-driven cancers.
Materials and methods
Cells
The murine pro-B-cell line Ba/F3 was maintained in RPMI-
1640 (Sigma-Aldrich, Darmstadt, Germany) containing 
l-glutamine (2 mM), penicillin (0.5 units/mL) + streptomycin 
(0.1 mg/mL; Sigma-Aldrich) and 10% fetal bovine serum 
(FBS; Biological Industries, Beit Haemek, Israel) supple-
mented with recombinant murine interleukin 3 (IL-3; 10 ng/
mL; Sigma-Aldrich). The generation and characterization of 
the Ba/F3 cells stably transfected with human wild type BLK 
(BLK-wt) or constitutively active BLK (Y501F) have been 
described previoulsly.25 Briefly, Ba/F3 BLK-wt and Ba/F3 
BLK (Y501F) were cultured in the presence of blasticidin 
(Invitrogen, Carlsbad, California, USA) and Ba/F3 BLK 
(Y501F) without IL-3. The cells were supplemented with 
fresh growth media the day before transplantation to ensure 
optimal growth conditions prior to inoculation.
Mice
7–9 weeks old athymic nude mice (NU/NU Nude, Foxn1nu; 
Charles River Laboratories, Wilmington, MA, USA) were 
allografted with the different Ba/F3 cell variants suspended 
in 100 µL of phosphate-buffered saline (PBS) by subcuta-
neous (SC) injection in each flank. Prior to SC injections, 
the mice were anesthetized with isoflurane (Piramal 
Healthcare UK Ltd, Morpeth, UK). Examination for palpa-
ble tumor formation and subsequent slide caliber measure-
ments of tumor sizes were performed three times per week 
throughout the experimental periods. Volumes of tumors 
were calculated as V = (L × W2)/2), with L and W represent-
ing tumor length and width (mm), respectively.
For the studies presented in Figures 1 and 2, both flanks 
of eight mice were injected with different numbers of Ba/
F3 BLK (Y501F) cells ranging from 0.25–25.0 × 106 cells 
per flank as specified in Figure 1(b). Once either the width 
or the length of a tumor reached the maximal allowed 
12 mm, the mice were individually sacrificed and their 
tumors were extracted for subsequent analysis.
For the studies presented in Figures 3 and 4, the mice 
were injected SC with Ba/F3 BLK (Y501F), Ba/F3 non-
transfected (NT), or Ba/F3 BLK-wt cells (2 × 106 cells/
injection) or PBS. When the mice injected with Ba/F3 
BLK (Y501F) cells developed palpable SC tumors they 
were treated with either dasatinib or matching vehicle con-
trol once daily, five times per week. Dasatinib (Cayman 
Chemical, Ann Arbor, MI, USA) and vehicle (10% dime-
thyl sulfoxide (DMSO)/90% (0.40 g/mL) 2-hydroxypro-
pyl-betacyclodextrin (Sigma-Aldrich)) was administrated 
via intraperitoneal injection (IP). The dose (40 mg/kg) was 
continuously adjusted to individual mouse weight meas-
ured three times per week. Mice injected with PBS, Ba/F3 
NT, or Ba/F3 BLK-wt cells were all treated IP with vehicle 
for comparative analysis. Once either the width or the 
length of tumor reached the maximal allowed 12 mm, the 
mice were sacrificed. All remaining mice were euthanized 
after maximum 3 weeks of treatment.
The experiments were authorized by The Animal 
Experiments Inspectorate (Dyreforsøgstilsynet) under the 
Ministry of Environment and Food of Denmark (Miljø- og 
fødevareministeriet) and performed according to the Danish 
legislation (License number: 2012-DY-2930-00748).
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Immunohistochemistry
Extracted tumors were fixed overnight in 4% paraformalde-
hyde (Santa Cruz Biotechnology, Dallas, TX, USA), rinsed 
in PBS, and stored in 70% ethanol (EtOH) at 4°C until par-
affin embedding. Antigen retrieval was performed by heat-
ing in tris–ethylenediaminetetraacetic acid (EDTA) buffer 
(pH 9; >98°C, 20 min). Samples were subjected to standard 
hematoxylin and eosin (H&E) staining, and immunohisto-
chemistry (IHC) was performed with anti-human-BLK anti-
body (sc-938; Santa Cruz Biotechnology). BLK positive 
and negative samples were included as controls for the anti-
BLK antibody staining. BioSiteHisto (BioSiteHisto Oy, 
Tampere, Finland) performed the staining.
Results
Ba/F3 BLK (Y501F) cells forms SC tumors  
in mice
To investigate the tumorigenic capacity of human BLK, 
and at the same time attempting to generate a mouse model 
where BLK oncology can be elaborately studied in the 
future, we initially examined whether cells solely trans-
formed by BLK were able to form tumors in mice. To this 
end, we used lymphoid Ba/F3 cells stably transformed 
with constitutive active human BLK (Y501F).25 These 
BLK activity–dependent cells were subcutaneously 
injected as allografts into the flanks of nude mice (NU/NU 
Nude Foxn1nu) and time was allowed to elapse while 
examining whether or not palpable SC tumors developed 
(illustrated in Figure 1(a)). Eight mice were initially 
injected with cells into both flanks. Each of the total 16 
flanks was injected with different amount of cells ranging 
from 0.25 to 25.0 × 106 cells/injection, as specified in 
Figure 1(b). Interestingly, we found that all mice eventu-
ally developed palpable SC tumors in all flanks as shown 
in Figure 1(c), although with variable pace and terminal 
size for the different cell number injections. Dissemination 
from primary tumors at sites of injection to close proxim-
ity skin areas was observed and the data presented in 
Figure 1(c) therefore represent the development in total SC 
tumor volume per flank. Tumors on flanks injected with 
1.5–3.0 × 106 cells developed relatively uniformly in terms 
of tumor onset time, volumetric progression, and time 
from onset to humane endpoint sacrifice as a result of 
tumor size. In contrast, increasing or decreasing the num-
ber of injected cells resulted in more heterogeneous tumor 
development with more variation in these parameters 
(Figure 1(c)). For the 2 × 106 cell injection, the time to 
tumor onset was 7 days (the average for all flanks was 
8.5 days ± 5.7 standard deviation (SD)) and the time from 
tumor onset to humane endpoint sacrifice as results of 
tumor size was 16 days (average for all flanks was 
16.4 days ± 7.8 SD). Therefore 2 × 106 cells per flank was 
Figure 1. Ba/F3 BLK (Y501F) cells form SC tumors in nude mice. (a) Schematic representation of experimental principle (SC: 
subcutaneous; Nude: NU/NU Nude Foxn1nu mouse). (b) Mouse identification numbers (Mouse ID) with corresponding tabulated 
numbers of Ba/F3 BLK (Y501F) cells injected into each flank. (c) Development of SC tumors in nude mice injected with Ba/F3 BLK 
(Y501F) cells. Each graph represents the tumor development in individual mice indicated by mouse ID (upper left corner), and each 
curve represents the total SC tumor volume per flank as a function of time (days after inoculation) until sacrifice when tumors 
reached maximal allowed size (12 mm on largest dimension). Total SC volumes of the tumors were calculated as described in 
Material and methods section.
4 Tumor Biology 
chosen as a suitable transplantation number with this 
model for onward studies. Figure 2(a) and (b) shows an in 
situ tumor in a mouse injected with 2 × 106 Ba/F3 BLK 
(Y501F) cells from the outside and inside, respectively. 
After sacrifice, the tumors were extracted and fixed in par-
aformaldehyde before paraffin embedding for immunohis-
tochemical analysis using anti-human-specific BLK 
antibodies to examine whether they really arose from the 
injected BLK-transformed Ba/F3 BLK (Y501F) cells. We 
found that all stained tumors were positive for human 
BLK, confirming that the tumors originated from the 
injected Ba/F3 BLK (Y501F) cells. Figure 2(c) and (d) 
shows representative images of an anti-BLK antibody 
stained tumor from a mouse injected with 2 × 106 Ba/F3 
BLK (Y501F) cells with Figure 2(e) and (f) as negative 
controls. Figure 2(g) depicts a sample of a Ba/F3 BLK 
(Y501F) tumor with overlaying skin tissue, showing that 
only the tumor tissue stained positive. Together, these 
results show that the allografted BLK-transformed Ba/F3 
BLK (Y501F) cells were able to form tumors and that a 
suitable number of Ba/F3 BLK (Y501F) cells for trans-
plantation in this model is 2 × 106 cells per flank.
Ba/F3 BLK (Y501F) tumors are BLK-induced 
and tumor growth is BLK activity–dependent
To investigate whether the Ba/F3 BLK (Y501F) tumors 
were BLK-induced and their growth is BLK activity–
dependent, we examined whether Ba/F3 NT cells (which 
do not express BLK) and stably transfected Ba/F3 cells 
expressing wild type BLK (BLK-wt) were also able to 
form allograft SC tumors in nude mice similar to Ba/F3 
BLK (Y501F) cells expressing constitutively active BLK. 
Furthermore, we examined whether the growth of estab-
lished Ba/F3 BLK (Y501F) tumors was inhibited by the 
clinical grade SFK inhibitor dasatinib which has already 
been shown to inhibit the activity of BLK in these cells 
in vitro.25 The experimental design is illustrated in Figure 3(a). 
Initially nude mice (NU/NU Nude Foxn1nu) were SC 
injected in each flank with 2 × 106 Ba/F3 NT, Ba/F3 
BLK-wt, Ba/F3 BLK (Y501F) cells or with PBS and were 
subsequently continuously examined for palpable SC 
tumor growth. As previously, we found that all mice trans-
planted with Ba/F3 BLK (Y501F) cells (n = 9) developed 
SC tumors; however, neither the PBS (n = 2), the Ba/F3 NT 
(n = 2), nor the Ba/F3 BLK-wt (n = 2) injected mice did 
(Figure 3(b) and (c)), indicating that the Ba/F3 BLK 
(Y501F) tumors were BLK-induced in a activity-depend-
ent way. Upon individual palpable tumor formation in the 
mice transplanted with Ba/F3 BLK (Y501F) cells, the 
mice were alternately allocated to treatment groups receiv-
ing either 40 mg/kg dasatinib (n = 5) or vehicle (n = 4). 
Each of the mice was treated for 3 weeks after individual 
palpable tumor formation and the growth of the tumors fol-
lowed by slide caliber measurements (Figure 3(b) and (c)). 
For comparative analysis, the PBS, Ba/F3 NT, and Ba/F3 
BLK-wt injected mice were also vehicle-treated and fol-
lowed for three subsequent weeks. The treatment of these 
mice was initiated when more than half (five of nine) of 
the Ba/F3 BLK (Y501F) transplanted mice had developed 
palpable tumors and concomitantly entered treatment. 
Figure 3(b) shows the development in average cumulative 
SC tumor volume for each of the groups of mice. The 
tumor growth (volume) measured continuously during the 
study was significantly reduced by treatment with dasat-
inib (p = 0.0021; Figure 3(b)), and some of the palpable 
tumors even became macroscopically undetectable fol-
lowing treatment. The weight of the extracted tumors after 
sacrifice was also reduced (p = 0.0045; Figure 3(c)). 
Importantly, dasatinib increased the survival of the tumor-
burdened mice significantly (p = 0.0320) as shown in 
Figure 3(d). These results confirm that the growth of the 
BLK-induced tumors was indeed BLK activity–dependent. 
Figure 4 shows representative images of the subcutis after 
sacrifice in mice injected with PBS, Ba/F3 NT, Ba/F3 
BLK-wt, or Ba/F3 BLK (Y501F) treated either with vehi-
cle or dasatinib.
Discussion
Members of the SFK group have long been known to be 
involved in cancers as promoters of malignancy.2 In addi-
tion, BLK has been suggested to have oncogenic proper-
ties and expressional associations with malignancy; 
however, the function of human BLK as an oncogene has 
been debated since Zhang et al. showed that BLK might 
function as a tumor suppressor in CML.24–32 In this study, 
we examined the oncogenic potential of human BLK in 
vivo by examining its tumorigenic and tumor progressive 
capability, using cells, which were transformed solely by 
BLK. Here, we show that macroscopic SC tumors devel-
oped in nude mice following SC allograft transplantation 
with lymphoid Ba/F3 BLK (Y501F) cells stably trans-
fected with, and transformed by, human BLK. The 
extracted tumors were positive for human BLK in IHC 
analysis, confirming the Ba/F3 BLK (Y501F) cell origin 
of the tumors. On the contrary, non-transfected Ba/F3 cells 
did not form tumors, indicating that the tumors formed by 
Ba/F3 cells transfected with active BLK (Y501F) were 
BLK-induced, since the cells themselves were not inher-
ently tumorigenic. In that sense, human BLK analogize 
other well-characterized oncogenes, like BCR-ABL and 
c-KIT, which are also able to transform the non-malignant 
Ba/F3 cells into tumor-inducing cells in murine in vivo 
models.33–35
All the mice injected with BLK-transformed Ba/F3 
BLK (Y501F) cells in this study (n = 17), irrespective of 
the number of cells transplanted, eventually developed 
tumors, many of which disseminated to adjacent skin 
areas. This shows that BLK-transformed cells are highly 
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Figure 2. Immunohistochemical analysis of Ba/F3 BLK (Y501F) tumors. (a) Epicutaneous and (b) subcutaneous photograph of 
tumor from mouse flank injected with 2 × 106 Ba/F3 BLK (Y501F) cells. Immunohistochemical analysis of human BLK protein 
expression in (c and d) tumor extracted from mouse flank injected with 2 × 106 Ba/F3 BLK (Y501F), (e and f) extracted heart as 
negative control, and (g) a BLK (Y501F) tumor with overlaying skin tissue.
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tumorigenic and BLK-induced tumor formation is robust 
in this novel in vivo model. Injection with 2 × 106 cells per 
flank was chosen as a suitable transplant to achieve rela-
tively uniform tumor development in terms of both time to 
tumor onset, assessed by first palpable tumor formation, 
and time from onset to termination due to humane end-
point sacrifice.
Previously, we have found that active but not wild type 
human BLK was able to transform Ba/F3 cells to exoge-
nous growth factor independency in vitro.25 Furthermore, 
we have shown that the BLK-induced growth factor inde-
pendency was lost by treatment with general SFK inhibi-
tors, including dasatinib, showing that the transforming 
ability of human BLK is kinase activity–dependent 
in vitro.25 Such activity dependency for transformation 
was also observed for the murine orthologue.24 In line 
with these findings, we now show that only the cells 
expressing constitutively active BLK, and not the cells 
expressing wild type BLK, can form tumors in vivo. In 
addition, we showed that the growth of BLK-induced 
tumors was inhibited with the SFK inhibitor dasatinib, 
indicating that the tumorigenecity of human BLK was 
activity-dependent. Hence, the presented data indicate 
that human BLK is a true proto-oncogene capable of 
inducing tumor growth in vivo in an activity-dependent 
manner. Taken together, this study provides new evidence 
supporting the hypothesis that human BLK might be an 
important oncogene driving certain human cancers, 
including CTCL. Since we found that dasatinib treatment 
inhibited the BLK-induced tumors and increased the sur-
vival of the tumor-burdened mice, this study also support 
the indication that dasatinib can be applied to target BLK 
activity in vivo.25 However, dasatinib is a broad-specific 
inhibitor of SFKs,11 thus for refinement of future cancer 
Figure 3. Ba/F3 BLK (Y501F) tumors are BLK-induced and tumor growth is BLK activity–dependent. Nude mice (NU/NU Nude 
Foxn1nu) were subcutaneously (SC) transplanted with 2 × 106 Ba/F3 NT, Ba/F3 BLK-wt, Ba/F3 BLK (Y501F) cells or injected 
with equivalent volumes of PBS. The Ba/F3 BLK (Y501F) cell–transplanted mice were individually treated with dasatinib (40 mg/
kg) or vehicle for 3 weeks following palpable tumor detection or until maximal allowable tumor size was reached (12 mm on 
largest dimension), at which point the mice were sacrificed and SC tumors were extracted. All other mice (PBS, Ba/F3 NT, and 
Ba/F3 BLK-wt injected) were treated with vehicle. (a) Schematic representation of experimental design. (b) Development in 
cumulative SC tumor volume (mm3) from initiation of treatment with either vehicle or 40 mg/kg dasatinib until termination of the 
experiment (day 21 post treatment initiation). Each datapoint represents group mean ± SEM. Volumes were calculated as described 
in Material and methods section (**: significant effect of treatment (p = 0.0021) applying two-way ANOVA for comparative Ba/F3 
BLK (Y501F) vehicle and dasatinib treatment values of tumor volume). (c) Weight of extracted tumors. Each datapoint represents 
the total weight (g) of extracted SC tumors from each mouse. Group mean ± SEM are shown (nd: non-detected; **: significantly 
different means (p = 0.0045) applying two-tailed t test comparing the vehicle and dasatinib treatment groups). (d) Survival curves 
(Kaplan–Meier) showing the percent survival for each group from initiation of treatment until experimental termination (day 21 
post treatment initiation; *: significantly different (p = 0.0320) survival curves comparing Ba/F3 BLK (Y501F) vehicle and dasatinib 
treatments applying log-rank (Mantel–Cox) test).
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therapy, more specific BLK-targeting agents should be 
sought for. The BLK-induced tumor model presented here 
can be valuable in the development of such therapies spe-
cifically targeting BLK.
Accumulating evidence, especially from several CTCL 
studies, the murine orthologue study, and this study, indi-
cates that BLK is a context-dependent oncogene, which in 
certain cases in BCR-ABL-driven disease might instead 
function as a tumor suppressor.24–27,30–32 As BLK interacts 
with negative regulators such as CSK and protein tyrosine 
phosphatases like SHP1, it is likely that the function of 
BLK depends on its interaction with these and other regu-
latory molecules.36 Accordingly, studies are in progress to 
elucidate the expression of negative regulators of BLK and 
compare putative interactions of BLK with phosphatases 
such as SHP1 in CTCL and BCR-ABL cells.
In conclusion, our study provides evidence indicating 
that human BLK is an activity-dependent bona fide proto-
oncogene capable of inducing tumor formation and pro-
gression. Furthermore, we established a novel mouse 
model of BLK-induced tumors, which can be used to study 
the oncological properties of BLK in vivo and be applied 
for preclinical in vivo evaluation of novel therapeutics tar-
geting the proto-oncogenic kinase BLK.
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